Electrophysiological profile of bepridil, a new anti-anginal drug with calcium blocking properties

Flammang, Daniel; Waynberger, M; Jansen, Feilx; Paillet, R; Coumel, P

doi:10.1093/oxfordjournals.eurheartj.a061537

Cited by 30 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The QRS duration was unaffected. These findings are consistent with clinical reports on ECG change (Duchene-Marullaz et al, 1983;Flammang et al, 1983) and suggest that bepridil at therapeutic concentrations lengthens ventricular repolarization without affecting the depolarization process. This has been confirmed by our mapping with modified bipolar electrodes on the posterior epicardial surface ofventricle.…”

Section: Discussionsupporting

confidence: 92%

“…Clinical studies have shown that bepridil causes a significant increase in QT and corrected QT-intervals of the ECG (Duchene-Marullaz et al, 1983;Flammang et al, 1983;Somberg et al, 1985;Singh et al, 1985). It is well known that such QT prolongation by antiarrhythmic agents is associated with an increased likelihood of malignant ventricular tachyarrhythmias of polymorphous configuration or of a Torsade de Pointes (T d P) pattern (Krikler & Curry, 1979;McComb et al, 1980;Keren et al, 1981;Laakso et al, 1981;Strasberg et al, 1981;Chow et al, 1984;Roden et al, 1986).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of bepridil on ventricular depolarization and repolarization of rabbit isolated hearts with particular reference to its possible proarrhythmic properties

Osaka

Kodama

Toyama

et al. 1988

British J Pharmacology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Effects of bepridil on ventricular depolarization and repolarization of rabbit isolated hearts with particular reference to its possible proarrhythmic properties

Osaka

Kodama

Toyama

et al. 1988

British J Pharmacology

View full text Add to dashboard Cite

“…Similar to lidoflazine, bepridil was initially reported to have antianginal as well as antiarrhythmic properties [58,104,124]. Subsequent studies in our [248] and other working groups [213] demonstrated a slight and linear increase in ERP and the QT interval.…”

Section: Characteristics Of Proarrhythmia After Drug-lnduced Qt Prolomentioning

confidence: 85%

QT-Interval prolonging drugs: Mechanisms and clinical relevance of their arrhythmogenic hazards

Zehender

Hohnloser

Just

1991

Cardiovasc Drug Ther

View full text Add to dashboard Cite

The antiarrhythmic principle of drug-induced QT-interval prolongation is well known. However, with the widespread use of the presently known and new Class III antiarrhythmic agents under investigation, and the growing number of agents not primarily designed as antiarrhythmic drugs that potentially cause QT prolongation, we have also become aware of the proarrhythmic hazards associated with many of these agents. The proarrhythmic risk differs markedly from one agent to another and interferes with many individual clinical variables (e.g., hypokalemia, sinus bradycardia). This paper summarizes the present data on the proarrhythmic risk of drug-induced QT prolongation, including the value and problems of the rate-corrected QT interval, the mechanisms involved in the genesis of proarrhythmia, and the clinical cofactors that facilitate the occurrence of proarrhythmic events. In addition, an extensive database provides information on the known proarrhythmic risk of all currently used QT-prolonging agents.

show abstract

“…In 20 patients bepridil appeared beneficial in suppressing AFL, atrial and ventricular extrasystoles [368]. Regarding ventricular arrhythmias bepridil was effective in non-responding VT in the dose of a single 800 mg followed by 500-600 mg as it prevented VT initiation in 66 % of the cases and caused side effects (paralytic ileus) in only 1 patient.…”

Section: Human Data On Hemodynamic Effects Of Monatepilmentioning

confidence: 99%

Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy

Szentandrássy

Nagy²,

Hegyi³

et al. 2014

CPD

View full text Add to dashboard Cite

Cardiac arrhythmias are a major cause of morbidity and mortality in the industrialized world. Among their treatment regimens one can find the calcium channel antagonists (CCAs), the class IV agents. In the cardiovascular system Land T-type calcium channels are found on vascular smooth muscle cells and cardiac myocytes with well defined physiological roles. Inhibition of calcium channels by CCAs has widely been used in clinical practice for several decades. Cardiovascular disorders are one of the many fields of medicine in which CCAs are used for various reasons and conditions. The three main indications of them are hypertension, angina and various cardiac arrhythmias. The most important classes of CCAs are dihydropyridines, phenylalkylamines and benzothiazepines but some newer compounds do not fall into any of these major classes. Dihydropyridines are not used in the antiarrhythmic therapy but are good vasodilators and antianginal agents. In contrast, phenylalkylamines and benzothiazepines exert cardiac actions in vivo and therefore these are one choice of antiarrhythmic drugs. This review focuses on phenylalkylamines, benzothiazepines and on new drugs with potential antiarrhythmic action in the heart as well as the mechanisms how calcium channels antagonism can lead to an antiarrhythmic action.

show abstract

Electrophysiological profile of bepridil, a new anti-anginal drug with calcium blocking properties

Cited by 30 publications

References 0 publications

Effects of bepridil on ventricular depolarization and repolarization of rabbit isolated hearts with particular reference to its possible proarrhythmic properties

Effects of bepridil on ventricular depolarization and repolarization of rabbit isolated hearts with particular reference to its possible proarrhythmic properties

QT-Interval prolonging drugs: Mechanisms and clinical relevance of their arrhythmogenic hazards

Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy

Contact Info

Product

Resources

About